China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc., granting METiS exclusive global development and commercialization rights to Evopoint’s SOS1 inhibitor. Under the agreement, METiS Therapeutics will pay Evopoint “hundreds of millions” of US dollars in total upfront payment and milestone payments, along with tiered royalties based on future global net sales.
Therapeutic Potential and Clinical Profile
Evopoint’s SOS1 inhibitor is designed to treat multiple solid tumors. The lead compound, XNW22013, has demonstrated excellent effects both alone and in combination with other drugs in preclinical trials, showing strong activity and high selectivity in inhibiting SOS1 in vitro. The compound also exhibits excellent characteristics in drug preparation and safety. In vivo studies in tumor models have shown that XNW22013 has a good tumor inhibition effect, whether used alone or in combination with other drugs.
Future Outlook
The global licensing agreement between Evopoint Biosciences and METiS Therapeutics highlights the potential of Evopoint’s SOS1 inhibitor in addressing significant unmet needs in cancer treatment. With robust preclinical data and a strong safety profile, XNW22013 is poised to make a meaningful impact on patient outcomes. METiS Therapeutics’ commitment to advancing the development and commercialization of this innovative therapy underscores its dedication to improving cancer care globally.-Fineline Info & Tech
